Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1, Randomized, Parallel Design Study to Determine the Bioequivalence and Investigate the Safety and Tolerability of Subcutaneous Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants

NCT07146750 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07146750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07146750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1, Randomized, Parallel Design Study to Determine the Bioequivalence and Investigate the Safety and Tolerability of Subcutaneous Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
August 25, 2025
Completion date
April 8, 2026
Enrollment
212 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers